ArticleScientific reports2026
Lycopene attenuates dexamethasone induced depression like behavior and immunological dysfunction via restoration of neuro-immune-metabolic homeostasis in rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic glucocorticoid therapy, while clinically indispensable, often induces debilitating neuropsychiatric side effects, including depression-like behaviors, alongside systemic immunosuppression and metabolic dysfunction. The convergence of central neurotoxicity and peripheral immune dysregulation presents a unique therapeutic challenge requiring multi-target interventions. This study investigated the prophylactic efficacy of lycopene against dexamethasone-induced behavioral, neurochemical, oxidative, inflammatory, and immunological perturbations in rats. Thirty-two adult male Sprague-Dawley rats were randomly assigned to four groups (n = 8): normal control, dexamethasone (2 mg/kg/day/intraperitoneal), lycopene (10 mg/kg/day/orally), and dexamethasone+lycopene combination. Treatments were administered daily for 21 days. Behavioral assessments (forced swim test, tail suspension test) were conducted. In frontal cortex and hippocampal tissues, neurochemical markers (brain-derived neurotrophic factor, gamma-aminobutyric acid, and acetylcholinesterase activity), neurotransmitters (serotonin, dopamine), oxidative stress markers (malondialdehyde, nitric oxide, reduced glutathione, superoxide dismutase, catalase), inflammatory cytokines (tumor necrosis factor-alpha and interleukin-6), and caspase-3 were quantified. In serum, fasting blood glucose, insulin, liver and kidney function markers, oxidative stress markers, inflammatory cytokines (interleukin-4, tumor necrosis factor-alpha, interferon-gamma), cluster of differentiation 4 and 8 concentrations (CD4, CD8), and complete blood count were analyzed. Dexamethasone significantly (p < 0.05) increased immobility time in behavioral tests, depleted serotonin and dopamine, elevated oxidative stress markers, and induced leukopenia with disrupted CD4/CD8 ratios. Lycopene co-treatment reversed behavioral despair, restored neurotransmitter homeostasis, attenuated oxidative-inflammatory cascades, normalized immune cell populations, and improved metabolic parameters. Lycopene provides integrated multi-system protection against glucocorticoid-induced neurobehavioral and immunological dysfunction, positioning it as a potential promising nutritional adjunct for patients requiring chronic corticosteroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.